{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:44:11Z","timestamp":1789688651080,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Based on findings of the Asian low-concentration atropine for myopia progression study, a concentration of 0.05% has been proposed as a good compromise between safety and efficacy for myopia control. However, no data on side effects have been published so far in Caucasian children receiving this dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prior to commencement of bilateral atropine treatment with 0.05% atropine, 19 myopic children aged 5 to 15\u00a0years were treated in only one eye at bedtime leaving the other eye as a control. Pupil size, accommodation amplitude and near visual acuity were measured at 10:00 a.m. the next day and compared to the untreated contralateral control eye. The results were then compared to a cohort of 18 children whose treatment with 0.01% atropine commenced in a similar fashion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twelve children (63%) reported visual impairment or reading difficulties. Anisocoria was 2.9\u2009\u00b1\u20091.1\u00a0mm. In comparison, 0.01% atropine led to a significantly less anisocoria of 0.8\u2009\u00b1\u20090.7\u00a0mm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Accommodation was decreased by\u2009\u2212\u20094.2\u2009\u00b1\u20093.8\u00a0D in 0.05% atropine treated eyes, whereas 0.01% atropine induced hypoaccommodation of\u2009\u2212\u20090.05\u2009\u00b1\u20092.5\u00a0D (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Near visual acuity was not significantly reduced in eyes treated with 0.05% atropine compared to 0.01% atropine (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.26).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared to 0.01%, our data indicate stronger more relevant side effects of 0.05% topical atropine in young Caucasian children with progressive myopia as recently reported in Asian children, potentially compromising acceptance and compliance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10792-021-01755-8","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T15:02:46Z","timestamp":1614265366000},"page":"2001-2008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: a pilot study"],"prefix":"10.1007","volume":"41","author":[{"given":"Lutz","family":"Joachimsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Farassat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bleul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"B\u00f6hringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf A.","family":"Lagr\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-8483","authenticated-orcid":false,"given":"Michael","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"issue":"5","key":"1755_CR1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S (2016) Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123(5):1036\u20131042. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.006","journal-title":"Ophthalmology"},{"issue":"7","key":"1755_CR2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/bjophthalmol-2015-307724","volume":"100","author":"AR Rudnicka","year":"2016","unstructured":"Rudnicka AR, Kapetanakis VV, Wathern AK, Logan NS, Gilmartin B, Whincup PH, Cook DG, Owen CG (2016) Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: implications for aetiology and early prevention. Br J Ophthalmol 100(7):882\u2013890. https:\/\/doi.org\/10.1136\/bjophthalmol-2015-307724","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1755_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10654-015-0010-0","volume":"30","author":"KM Williams","year":"2015","unstructured":"Williams KM, Verhoeven VJ, Cumberland P, Bertelsen G, Wolfram C, Buitendijk GH, Hofman A, van Duijn CM, Vingerling JR, Kuijpers RW, Hohn R, Mirshahi A, Khawaja AP, Luben RN, Erke MG, von Hanno T, Mahroo O, Hogg R, Gieger C, Cougnard-Gregoire A, Anastasopoulos E, Bron A, Dartigues JF, Korobelnik JF, Creuzot-Garcher C, Topouzis F, Delcourt C, Rahi J, Meitinger T, Fletcher A, Foster PJ, Pfeiffer N, Klaver CC, Hammond CJ (2015) Prevalence of refractive error in europe: the european eye epidemiology (E(3)) consortium. Eur J Epidemiol 30(4):305\u2013315. https:\/\/doi.org\/10.1007\/s10654-015-0010-0","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"1755_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.ajo.2014.07.033","volume":"158","author":"CM McKnight","year":"2014","unstructured":"McKnight CM, Sherwin JC, Yazar S, Forward H, Tan AX, Hewitt AW, Pennell CE, McAllister IL, Young TL, Coroneo MT, Mackey DA (2014) Myopia in young adults is inversely related to an objective marker of ocular sun exposure: the Western Australian Raine cohort study. Am J Ophthalmol 158(5):1079\u20131085. https:\/\/doi.org\/10.1016\/j.ajo.2014.07.033","journal-title":"Am J Ophthalmol"},{"key":"1755_CR5","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.exer.2013.02.007","volume":"114","author":"M Feldkaemper","year":"2013","unstructured":"Feldkaemper M, Schaeffel F (2013) An updated view on the role of dopamine in myopia. Exp Eye Res 114:106\u2013119. https:\/\/doi.org\/10.1016\/j.exer.2013.02.007","journal-title":"Exp Eye Res"},{"issue":"12","key":"1755_CR6","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ophtha.2006.06.033","volume":"113","author":"S Vitale","year":"2006","unstructured":"Vitale S, Cotch MF, Sperduto R, Ellwein L (2006) Costs of refractive correction of distance vision impairment in the United States, 1999\u20132002. Ophthalmology 113(12):2163\u20132170. https:\/\/doi.org\/10.1016\/j.ophtha.2006.06.033","journal-title":"Ophthalmology"},{"issue":"6","key":"1755_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.preteyeres.2012.06.004","volume":"31","author":"DI Flitcroft","year":"2012","unstructured":"Flitcroft DI (2012) The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res 31(6):622\u2013660. https:\/\/doi.org\/10.1016\/j.preteyeres.2012.06.004","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"1755_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","volume":"134","author":"JW Tideman","year":"2016","unstructured":"Tideman JW, Snabel MC, Tedja MS, van Rijn GA, Wong KT, Kuijpers RW, Vingerling JR, Hofman A, Buitendijk GH, Keunen JE, Boon CJ, Geerards AJ, Luyten GP, Verhoeven VJ, Klaver CC (2016) Association of axial length with risk of uncorrectable visual impairment for Europeans with Myopia. JAMA Ophthalmol 134(12):1355\u20131363. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.4009","journal-title":"JAMA Ophthalmol"},{"issue":"13","key":"1755_CR9","doi-asserted-by":"publisher","first-page":"7871","DOI":"10.1167\/iovs.13-12403","volume":"54","author":"Group C","year":"2013","unstructured":"Group C (2013) Myopia stabilization and associated factors among participants in the correction of myopia evaluation trial (COMET). Investig Ophthalmol Vis Sci 54(13):7871\u20137884. https:\/\/doi.org\/10.1167\/iovs.13-12403","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"3","key":"1755_CR10","doi-asserted-by":"publisher","first-page":"M132","DOI":"10.1167\/iovs.18-25955","volume":"60","author":"JS Wolffsohn","year":"2019","unstructured":"Wolffsohn JS, Kollbaum PS, Berntsen DA, Atchison DA, Benavente A, Bradley A, Buckhurst H, Collins M, Fujikado T, Hiraoka T, Hirota M, Jones D, Logan NS, Lundstrom L, Torii H, Read SA, Naidoo K (2019) IMI\u2014clinical Myopia control trials and instrumentation report. Invest Ophthalmol Vis Sci 60(3):M132\u2013M160. https:\/\/doi.org\/10.1167\/iovs.18-25955","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1755_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/aos.13403","volume":"95","author":"S Xiong","year":"2017","unstructured":"Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, Lv M, He X, Xu X (2017) Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol 95(6):551\u2013566. https:\/\/doi.org\/10.1111\/aos.13403","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"1755_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2020.10834","volume":"324","author":"JJ Walline","year":"2020","unstructured":"Walline JJ, Walker MK, Mutti DO, Jones-Jordan LA, Sinnott LT, Giannoni AG, Bickle KM, Schulle KL, Nixon A, Pierce GE, Berntsen DA, BS Group (2020) Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children: the BLINK randomized clinical trial. JAMA 324(6):571\u2013580. https:\/\/doi.org\/10.1001\/jama.2020.10834","journal-title":"JAMA"},{"issue":"6","key":"1755_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","volume":"135","author":"Q Gong","year":"2017","unstructured":"Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G, Liu L (2017) Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis. JAMA Ophthalmol 135(6):624\u2013630. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1091","journal-title":"JAMA Ophthalmol"},{"key":"1755_CR14","first-page":"139","volume":"2","author":"H Derby","year":"1874","unstructured":"Derby H (1874) On the atropine treatment of acquired and progressive myopia. Trans Am Ophthalmol Soc 2:139\u2013154","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"2","key":"1755_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","volume":"157","author":"A Chia","year":"2014","unstructured":"Chia A, Chua WH, Wen L, Fong A, Goon YY, Tan D (2014) Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol 157(2):451\u2013457. https:\/\/doi.org\/10.1016\/j.ajo.2013.09.020","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1755_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP (2019) Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology 126(1):113\u2013124. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029","journal-title":"Ophthalmology"},{"issue":"3","key":"1755_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40123-019-0194-6","volume":"8","author":"L Joachimsen","year":"2019","unstructured":"Joachimsen L, Bohringer D, Gross NJ, Reich M, Stifter J, Reinhard T, Lagreze WA (2019) A pilot study on the efficacy and safety of 0.01% atropine in German schoolchildren with progressive myopia. Ophthalmol Ther 8(3):427\u2013433. https:\/\/doi.org\/10.1007\/s40123-019-0194-6","journal-title":"Ophthalmol Ther"},{"issue":"7","key":"1755_CR18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, Ko ST, Young AL, Tham CC, Chen LJ, Pang CP (2020) Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology 127(7):910\u2013919. https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.011","journal-title":"Ophthalmology"},{"issue":"12","key":"1755_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/OPX.0000000000000037","volume":"90","author":"J Cooper","year":"2013","unstructured":"Cooper J, Eisenberg N, Schulman E, Wang FM (2013) Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci 90(12):1467\u20131472. https:\/\/doi.org\/10.1097\/OPX.0000000000000037","journal-title":"Optom Vis Sci"},{"issue":"8","key":"1755_CR20","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.1111\/aos.14166","volume":"97","author":"M Sacchi","year":"2019","unstructured":"Sacchi M, Serafino M, Villani E, Tagliabue E, Luccarelli S, Bonsignore F, Nucci P (2019) Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients. Acta Ophthalmol 97(8):e1136\u2013e1140. https:\/\/doi.org\/10.1111\/aos.14166","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"1755_CR21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","volume":"93","author":"M Diaz-Llopis","year":"2018","unstructured":"Diaz-Llopis M, Pinazo-Duran MD (2018) Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness. Arch Soc Esp Oftalmol 93(4):182\u2013185. https:\/\/doi.org\/10.1016\/j.oftal.2017.12.015","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"10","key":"1755_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00347-007-1626-6","volume":"104","author":"J Buhren","year":"2007","unstructured":"Buhren J, Kohnen T (2007) Application of wavefront analysis in clinical and scientific settings. From irregular astigmatism to aberrations of a higher order\u2013part i: basic principles. Ophthalmologe 104(10):909\u2013923","journal-title":"Ophthalmologe"},{"issue":"3","key":"1755_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/jop.1999.15.257","volume":"15","author":"EJ German","year":"1999","unstructured":"German EJ, Wood D, Hurst MA (1999) Ocular effects of antimuscarinic compounds: is clinical effect determined by binding affinity for muscarinic receptors or melanin pigment? J Ocul Pharmacol Ther 15(3):257\u2013269. https:\/\/doi.org\/10.1089\/jop.1999.15.257","journal-title":"J Ocul Pharmacol Ther"},{"issue":"11","key":"1755_CR24","first-page":"812","volume":"119","author":"Y Nishiyama","year":"2015","unstructured":"Nishiyama Y, Moriyama M, Fukamachi M, Uchida A, Miyaushiro H, Kurata A, Tokoro T, Ohno-Matsui K (2015) Side effects of low dose atropine. Nippon Ganka Gakkai Zasshi 119(11):812\u2013816","journal-title":"Nippon Ganka Gakkai Zasshi"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-01755-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T10:26:38Z","timestamp":1622629598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-01755-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-01755-8","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from the parents of the patients for participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation"}},{"value":"Patients signed informed consent regarding publishing their data and photographs. Furthermore, this study does not contain any personal information that could lead to the identification of the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (application no. 287\/16) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}